Ad-hoc: Marinomed Biotech AG announces unanimous approval of the restructuring plan by creditors
Ad-hoc: Marinomed Biotech AG begins contract negotiations for the sale of the Carragelose portfolio
Ad-hoc: Marinomed Biotech AG resolves capital increase excluding statutory subscription rights by issuing 154,053 no-par value bearer shares at an issue price of EUR 5 per share
Ad-hoc: Marinomed Biotech AG sets price range for potential 10% capital increase and potential second capital increase, in each case excluding statutory subscription rights
Lucia Ziegler, MSc
Head of Investor & Public Relations